Anxiety & Stress Disorders

Psychiatric Times wants to help you, as clinicians, support every patient.

Here are highlights from the week in Psychiatric Times.

Following the vote of the US Food and Drug Administration Psychopharmacologic Drugs Advisory Committee, Lykos has released a statement on MDMA-assisted therapy.

Experts shared the study results in a poster presentation at the 2024 ASCP Annual Meeting.

Here are highlights from the week in Psychiatric Times.

An expert discusses how the risks of benzodiazepine prescribing have been exaggerated in the minds of government officials, critics, and the public at large.

Psychiatric Times Editor-in-Chief shares his thoughts on the FDA Psychopharmacologic Drugs Advisory Committee decision for MDMA.

The FDA Psychopharmacologic Drugs Advisory Committee voted against recommending approval for psychedelic MDMA.

Write to us now to be part of our series focused on stress and anxiety this month.

The FDA Meeting of the Psychopharmacologic Drugs Advisory Committee evaluating the New Drug Application for MDMA is happening now. How do clinicians feel about this potential treatment for PTSD?

A lead educator and clinical consultant in the Lykos Therapeutics MDMA Therapist Education Program discusses MDMA-assisted therapy’s potential.

Some clinicians are skeptical about the potential of MDMA-assisted therapy...

If approved, how will MDMA-assisted therapy impact clinical psychiatry? The CEO of Lykos Therapeutics shares her thoughts.

In advance of the June 4 FDA Advisory Committee Meeting on MDMA-assisted therapy, we sat down with Alejandra Alva, MD, to get his first impressions.

What is new in research on stress and anxiety disorders?

According to the chief medical officer of MindMed, it is time to look past the history of LSD.

Here are highlights from the fourth day of this year’s APA Annual Meeting.

Generalized anxiety disorder: has it been sidelined by MDD? MM-120 is a new treatment under investigation for this disorder, making waves.

What are the connections between what we eat and disorders such as anxiety and depression?

While benzodiazepine prescribing certainly carries risks, those risks have been demonstrably exaggerated in the minds of government officials, critics, and the public at large.

Vistagen has enrolled the first participant in the PALISADE-3 phase 3 trial of fasedienol for the treatment of social anxiety disorder.

From an update on Prism for PTSD to the efficacy of home-use transcranial direct current stimulation for MDD, here are highlights from the week in Psychiatric Times.

What is new in research on cannabis?

The US Food and Drug Administration has granted breakthrough designation to MindMed’s lysergide d-tartrate program (MM-120) for the treatment of generalized anxiety disorder.

Neuropsychiatric disorders regularly occur following traumatic brain injury and are often diagnosed within the first year postinjury. Diagnosis and treatment of neuropsychiatric disorders can be difficult due to a number of interacting factors, such as preinjury psychiatric history, lesion location, injury severity, substance misuse, and psychosocial complications. Clinicians should use a highly individualized approach to diagnosis and treatment planning.

These partnerships aim to address the mental health needs of underserved populations, including individuals with clinical depression, anxiety, and mood disorders.

New research finds whole-family collaborative care digital mental health interventions help manage disordered eating behaviors in adolescents aged 13-17.

From the impact of BMI on clinical features of bipolar disorder to FDA approval of the first integrated TMS system for MDD and OCD, here are highlights from the week in Psychiatric Times.

What is new in research on depression?

The FDA granted clearance for a transcranial magnetic stimulation technology indicated for major depressive disorder and obsessive-compulsive disorder.